Stuart Coupland

Stuart Coupland

PhD

Affiliate Investigator, Neuroscience

Ottawa Hospital Research Institute

Associate Professor, Faculty of Medicine Department of Ophthalmology

University of Ottawa

Associate Professor, Faculty of Medicine Department of Cellular and Molecular Medicine

University of Ottawa

Director, Structural and Functional Retinal Imaging Unit

The Ottawa Hospital

Contact

613-737-8519

Bio

I completed my PhD in experimental psychology at Simon Fraser University in Burnaby, British Columbia in 1979. Following this, I was awarded the J.B.R. Cosgrove Research Fellowship at the Montreal Neurological Institute in the Department of Neuro-Ophthalmology with a cross-appointment in the Ophthalmology Department at McGill University. Following, I was awarded a 3-year postdoctoral fellowship from the Multiple Sclerosis Society of Canada which was also taken in the Department of Neuro-Ophthalmology at the Montreal Neurological Institute. In 1982, I moved to Calgary where I held academic appointments in the Departments of Pediatrics, Clinical Neurosciences and Surgery at the University of Calgary. During that time I was Director of the Sensory Physiology Laboratory at Alberta Children's Hospital for the next 16 years. In 1998 I accepted an appointment at the University of Ottawa as Associate Professor in Ophthalmology and became Director of Structural and Functional Imaging Unit at the University of Ottawa Eye Institute. In 2005 I received the American Academy of Ophthalmology Achievement Award. In 2012 I received a cross-appointment in the Cellular and Molecular Medicine Department.

Research Goals and Interests

My clinical research interests involve the study of retinal structure and function in patients with age-related macular degeneration and other macular diseases. Our laboratory is also involved in developing sensitive screening technologies to detect early retinal toxicity in patients taking chloroquine and hydroxychloroquine, the drugs used to treat rheumatoid arthritis. Our basic research laboratory investigates retinal function in animal models of retinal degeneration and in gene therapy treatment for retinal diseases.

Screening for Retinal Toxicity

The multifocal electroretinogram is considered to be the modern day standard in visual electrodiagnostics of central electroretinal function. The multifocal ERG (mERG) is the simultaneous recording of the central, localized electroretinal function from 61 regions of the central 60° in the posterior pole. This technology allows us to form a functional topographic map where we can assess central electrorintal function in disease states including retinitis pigmentosa, cone dystrophies, as well as assess the effect of retinal toxic medication. One area of research interest has been in applying mERG to assess early chloroquine and hydroxychloroquine toxicity in patients taking these drugs. Chloroquine (CQ) and hydroxychloroquine (HCQ) are used in the long-term treatment of rheumatic and dermatologic diseases. The prevalence of toxicity rises to 1% after 5 years of continuous treatment and greatly increases when patients have used the drug continuously for 2 decades. Early detection of CQ/HCQ retinopathy is paramount as there are no treatment options and vision loss is irreversible, and often progresses despite discontinuation of drug therapy. We are using mERG and as well as spectral domain optical coherence tomography to assess patients on long-term CQ and HCQ therapy.

 

 


News


Related Research at The Ottawa Hospital